NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, Price Target & More

Get Started

$3.20 -0.20 (-5.88 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$3.20

Today's Range$3.10 - $3.45

52-Week Range$1.55 - $5.75

Volume1.20 million shs

Average Volume481,161 shs

Market Capitalization$161.66 million

P/E Ratio-2.91

Dividend YieldN/A

Beta2.38

About AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:ACRX

CUSIPN/A

Webwww.acelrx.com

Phone650-216-3500

Debt

Debt-to-Equity Ratio-0.20

Current Ratio4.05

Quick Ratio4.00

Price-To-Earnings

Trailing P/E Ratio-2.91

Forward P/E Ratio-3.76

P/E GrowthN/A

Sales & Book Value

Annual Sales$7.99 million

Price / Sales20.55

Cash FlowN/A

Price / CashN/A

Book Value($0.91) per share

Price / Book-3.52

Profitability

EPS (Most Recent Fiscal Year)($1.10)

Net Income$-51,500,000.00

Net Margins-909.33%

Return on EquityN/A

Return on Assets-62.92%

Miscellaneous

Employees41

Outstanding Shares51,320,000

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals (NASDAQ:ACRX) issued its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.01. The specialty pharmaceutical company earned $0.34 million during the quarter, compared to the consensus estimate of $0.78 million. View AcelRx Pharmaceuticals' Earnings History.

What price target have analysts set for ACRX?

7 brokers have issued 1 year price objectives for AcelRx Pharmaceuticals' shares. Their forecasts range from $2.00 to $8.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $5.40 in the next twelve months. View Analyst Ratings for AcelRx Pharmaceuticals.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a decrease in short interest in April. As of April 13th, there was short interest totalling 3,186,890 shares, a decrease of 31.0% from the March 30th total of 4,617,564 shares. Based on an average trading volume of 271,624 shares, the days-to-cover ratio is currently 11.7 days. Approximately 7.8% of the shares of the stock are sold short.

Who are some of AcelRx Pharmaceuticals' key competitors?

Some companies that are related to AcelRx Pharmaceuticals include Rigel Pharmaceuticals (RIGL), Aduro BioTech (ADRO), ChemoCentryx (CCXI), Lannett (LCI), Odonate Therapeutics (ODT), Ziopharm Oncology (ZIOP), BeyondSpring (BYSI), Keryx Biopharmaceuticals (KERX), CannTrust (CNTTF), AC Immune (ACIU), Aclaris Therapeutics (ACRS), Akebia Therapeutics (AKBA), Stemline Therapeutics (STML), Kura Oncology (KURA) and Prothena (PRTA).

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:

Dr. Pamela Pierce Palmer M.D., Ph.D., Co-Founder, Chief Medical Officer and Director (Age 55)
Ms. Jane Wright-Mitchell, Chief Legal Officer (Age 49)
Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)
Mr. Anil N. Dasu, Chief Engineering Officer (Age 55)
Mr. Vincent J. Angotti, CEO & Director (Age 50)

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

News stories about ACRX stock have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AcelRx Pharmaceuticals earned a coverage optimism score of 0.21 on Accern's scale. They also assigned media stories about the specialty pharmaceutical company an impact score of 46.65 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.45%), Northern Trust Corp (0.18%), A.R.T. Advisors LLC (0.14%) and GSA Capital Partners LLP (0.11%). Company insiders that own AcelRx Pharmaceuticals stock include Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Perceptive Advisors Llc, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.

Which major investors are selling AcelRx Pharmaceuticals stock?

ACRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and A.R.T. Advisors LLC. Company insiders that have sold AcelRx Pharmaceuticals company stock in the last year include Lawrence G Hamel and Life Sciences Maste Perceptive. View Insider Buying and Selling for AcelRx Pharmaceuticals.

Which major investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP and Northern Trust Corp. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $3.20.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $161.66 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]

MarketBeat Community Rating for AcelRx Pharmaceuticals (ACRX)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		290 (Vote Outperform)
Underperform Votes:		221 (Vote Underperform)
Total Votes:		511

MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

AcelRx Pharmaceuticals (NASDAQ:ACRX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

7 Wall Street analysts have issued ratings and price targets for AcelRx Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.40, suggesting that the stock has a possible upside of 68.75%. The high price target for ACRX is $8.00 and the low price target for ACRX is $2.00. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.57	2.57	2.57	2.57
Ratings Breakdown:	0 Sell Rating(s) 3 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$5.40	$5.40	$6.8333	$6.8333
Price Target Upside:	68.75% upside	200.00% upside	279.63% upside	279.63% upside

AcelRx Pharmaceuticals (NASDAQ:ACRX) Consensus Price Target History

Price Target History for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ:ACRX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
10/27/2017	HC Wainwright	Reiterated Rating	Buy	$5.00	N/A
10/13/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$2.00	N/A
10/13/2017	Royal Bank of Canada	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00	N/A
10/13/2017	Jefferies Group	Downgrade	Buy ➝ Hold		N/A
10/12/2017	Roth Capital	Set Price Target	Buy	$8.00	N/A
8/9/2017	Stifel Nicolaus	Upgrade	Hold ➝ Buy		High
8/1/2017	Cowen	Reiterated Rating	Hold		High

(Data available from 5/25/2016 forward)

AcelRx Pharmaceuticals (NASDAQ:ACRX) Earnings History and Estimates Chart

Earnings by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ:ACRX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.00)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.24)	($0.24)	($0.24)
Q2 2018	1	($0.29)	($0.29)	($0.29)
Q3 2018	1	($0.17)	($0.17)	($0.17)
Q4 2018	1	($0.30)	($0.30)	($0.30)

AcelRx Pharmaceuticals (NASDAQ ACRX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018	Q1	($0.24)	($0.23)	$0.78 million	$0.34 million	View	N/A
3/8/2018	Q4 2017	($0.20)	($0.20)	$2.90 million	$0.74 million	View	N/A
11/9/2017	Q3 2017	($0.26)	($0.28)	$2.46 million	$1.49 million	View	N/A
8/1/2017	Q2 2017	($0.28)	($0.29)	$2.63 million	$2.66 million	View	Listen
5/8/2017	Q1 2017	($0.28)	($0.34)	$2.36 million	$3.11 million	View	Listen
3/2/2017	Q4 2016	($0.23)	($0.21)	$3.05 million	$6.44 million	View	Listen
11/1/2016	Q316	($0.23)	($0.25)	$2.89 million	$1.60 million	View	N/A
7/28/2016	Q216	($0.22)	($0.24)	$2.17 million	$4.53 million	View	Listen
5/2/2016	Q1 2016	($0.22)	($0.22)	$2.05 million	$3.03 million	View	N/A
3/7/2016	Q415	($0.10)	($0.24)	$4.97 million	$1.73 million	View	Listen
10/29/2015	Q315	($0.23)	$0.11	$1.75 million	$13.90 million	View	Listen
8/3/2015	Q215	($0.26)	($0.20)	$0.30 million	$1.92 million	View	Listen
5/4/2015	Q115	($0.28)	($0.27)	$0.40 million	$0.18 million	View	N/A
3/9/2015	Q4 2014	($0.33)	($0.32)		$0.23 million	View	N/A
11/10/2014	Q4 2014	($0.33)	($0.32)	$4.95 million	$4.83 million	View	N/A
8/11/2014	Q214	($0.27)	($0.34)	$0.20 million	$0.07 million	View	N/A
5/8/2014	Q114	($0.23)	($0.22)	$0.28 million	$0.10 million	View	N/A
3/3/2014	Q413	($0.17)	($0.18)	$4.93 million	$27.60 million	View	N/A
11/5/2013	Q313	($0.19)	($0.26)	$0.40 million	$0.55 million	View	N/A
8/12/2013	Q2 2013	($0.22)	($0.22)	$1.73 million	$0.4070 million	View	Listen
5/8/2013	Q1 2013	($0.26)	($0.34)	$0.68 million	$0.94 million	View	N/A
3/12/2013	Q4 2012	($0.39)	($0.41)			View	N/A
11/6/2012	Q312	($0.38)	($0.38)			View	N/A
8/9/2012	Q2 2012	($0.39)	($0.35)			View	N/A
5/8/2012	Q1 2012	($0.35)	($0.36)			View	N/A
3/20/2012	Q4 2011	($0.39)	($0.33)			View	N/A
11/8/2011	Q3 2011	($0.34)	($0.30)			View	N/A
8/11/2011	Q2 2011	($0.32)	($0.25)			View	N/A
5/12/2011	Q1 2011	($0.22)	($0.30)			View	N/A
3/24/2011	Q4 2010		($5.23)			View	N/A

(Earnings results data provided by Zacks Investment Research)

AcelRx Pharmaceuticals (NASDAQ:ACRX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.50%
Institutional Ownership Percentage: 8.94%

Insider Trading History for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/14/2017	Mark G Edwards	Director	Buy	30,000	$1.90	$57,000.00	150,000
11/13/2017	Raffi Asadorian	CFO	Buy	5,000	$1.94	$9,700.00	12,000
10/2/2017	Lawrence G Hamel	Insider	Sell	10,161	$5.29	$53,751.69	16,379
9/11/2017	Raffi Asadorian	CFO	Buy	7,000	$3.24	$22,680.00	7,000
8/24/2017	Mark G Edwards	Director	Buy	5,000	$3.02	$15,100.00	115,200
8/24/2017	Vincent J Angotti	CEO	Buy	15,000	$3.00	$45,000.00	15,000
8/22/2017	Pamela P. Palmer	Insider	Buy	10,000	$2.95	$29,500.00
6/19/2017	Life Sciences Maste Perceptive	Major Shareholder	Sell	875,000	$2.40	$2,100,000.00
9/29/2016	Perceptive Advisors Llc	Major Shareholder	Sell	216,500	$3.92	$848,680.00
9/15/2016	Perceptive Advisors Llc	Major Shareholder	Sell	392,850	$3.70	$1,453,545.00
5/13/2016	Howard B Rosen	CEO	Buy	10,206	$3.26	$33,271.56	50,000
5/12/2016	Mark G Edwards	Director	Buy	15,000	$3.15	$47,250.00	105,000
11/18/2015	Perceptive Advisors Llc	Major Shareholder	Sell	176,200	$5.35	$942,670.00
11/6/2015	Perceptive Advisors Llc	Major Shareholder	Sell	92,100	$4.59	$422,739.00
9/9/2015	Perceptive Advisors Llc	Major Shareholder	Sell	310,000	$4.18	$1,295,800.00
5/7/2015	Mark G Edwards	Director	Buy	40,000	$3.13	$125,200.00
3/10/2014	Mark Wan	Director	Sell	1,000,000	$12.35	$12,350,000.00
11/7/2013	Perceptive Advisors Llc	major shareholder	Buy	200,000	$6.51	$1,302,000.00
11/4/2013	Perceptive Advisors Llc	major shareholder	Buy	155,000	$6.87	$1,064,850.00
11/1/2013	Perceptive Advisors Llc	Major Shareholder	Buy	360,660	$6.91	$2,492,160.60
9/20/2013	Guy Nohra	Director	Sell	158,153	$10.59	$1,674,840.27
9/18/2013	Guy Nohra	Director	Sell	128,780	$10.42	$1,341,887.60
7/23/2013	Perceptive Advisors Llc	Major Shareholder	Buy	850,000	$11.65	$9,902,500.00
6/6/2013	Mark G Edwards	Director	Buy	10,000	$8.10	$81,000.00
5/28/2013	Adrian Adams	Director	Buy	75,000	$8.19	$614,250.00
12/7/2012	Mark A Wan	Director	Buy	2,416,918	$3.31	$7,999,998.58

(Data available from 1/1/2013 forward)

AcelRx Pharmaceuticals (NASDAQ ACRX) News Headlines

Source:

Date	Headline
	AcelRx Pharma (ACRX) Says FDA Accepts NDA for DSUVIA; 11/3 PDUFA www.streetinsider.com - May 25 at 8:18 AM
	Leerink-led investors acquire Three Arch stake in AcelRx; shares up 7% seekingalpha.com - May 24 at 8:19 AM
	FDA accepts AcelRx's Dsuvia NDA, shares up 13% premarket seekingalpha.com - May 24 at 8:19 AM
	AcelRx announces FDA acceptance of NDA for DSUVIA finance.yahoo.com - May 24 at 8:19 AM
	Brokerages Anticipate AcelRx Pharmaceuticals (ACRX) Will Announce Quarterly Sales of $980,000.00 www.americanbankingnews.com - May 24 at 2:32 AM
	BRIEF-Three Arch's Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry ... www.reuters.com - May 23 at 8:18 AM
	Three Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and ... www.prnewswire.com - May 23 at 8:18 AM
	Three Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry Ventures finance.yahoo.com - May 23 at 8:18 AM
	-$0.22 EPS Expected for AcelRx Pharmaceuticals (ACRX) This Quarter www.americanbankingnews.com - May 22 at 5:14 PM
	AcelRx Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference finance.yahoo.com - May 22 at 5:09 PM
	Why You Need To Look At This Factor Before Buying AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) finance.yahoo.com - May 18 at 8:39 AM
	Zacks Investment Research Upgrades AcelRx Pharmaceuticals (ACRX) to Buy www.americanbankingnews.com - May 15 at 4:26 PM
	Blog Exposure - AcelRx Pharma Resubmitted New Drug Application for DSUVIA with FDA finance.yahoo.com - May 11 at 8:26 AM
	AcelRx Pharmaceuticals (ACRX) Announces Earnings Results, Beats Estimates By $0.01 EPS www.americanbankingnews.com - May 10 at 6:12 PM
	AcelRx Pharma (ACRX) Resubmits NDA for DSUVIA www.streetinsider.com - May 10 at 8:23 AM
	AcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 10 at 8:23 AM
	Edited Transcript of ACRX earnings conference call or presentation 9-May-18 8:30pm GMT finance.yahoo.com - May 10 at 8:23 AM
	AcelRx refiles U.S. marketing application for Dsuvia, action date Q4; shares up 10% premarket seekingalpha.com - May 9 at 5:35 PM
	Want To Invest In AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)? Here’s How It Performed Lately finance.yahoo.com - May 9 at 5:35 PM
	AcelRx Pharmaceuticals: 1Q Earnings Snapshot finance.yahoo.com - May 9 at 5:35 PM
	AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results finance.yahoo.com - May 9 at 5:35 PM
	AcelRx resubmits New Drug Application for DSUVIA™ finance.yahoo.com - May 9 at 8:18 AM
	Stocks Under Scanner in the Medical Equipment Space – Accuray and Two more Stock Research Monitor: ACRX, and CHFS finance.yahoo.com - May 9 at 8:18 AM
	AcelRx Pharmaceuticals (ACRX) Expected to Announce Quarterly Sales of $780,000.00 www.americanbankingnews.com - May 7 at 4:38 AM
	AcelRx Pharmaceuticals (ACRX) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - May 6 at 7:39 PM
	AcelRx Pharmaceuticals (ACRX) Expected to Announce Earnings of -$0.24 Per Share www.americanbankingnews.com - May 5 at 9:39 AM
	ValuEngine Upgrades AcelRx Pharmaceuticals (ACRX) to "Sell" www.americanbankingnews.com - May 4 at 3:35 PM
	AcelRx Pharmaceuticals (ACRX) to Release Quarterly Earnings on Wednesday www.americanbankingnews.com - May 2 at 9:42 PM
	PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018 www.prnewswire.com - May 2 at 8:20 AM
	AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia ... www.prnewswire.com - May 2 at 8:20 AM
	AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems finance.yahoo.com - April 30 at 8:23 AM
	European advisory group backs AcelRx's pain med Dzuveo; shares up 11% seekingalpha.com - April 27 at 5:15 PM
	BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In ... www.reuters.com - April 27 at 8:29 AM
	AcelRx Pharma (ACRX) Receives Positive CHMP Opinion for DZUVEO for Management of Pain www.streetinsider.com - April 27 at 8:29 AM
	AcelRx receives positive CHMP opinion for DZUVEO™ for management of acute moderate to severe pain in medically monitored settings finance.yahoo.com - April 27 at 8:29 AM
	Short Interest in AcelRx Pharmaceuticals (ACRX) Declines By 31.0% www.americanbankingnews.com - April 27 at 1:24 AM
	AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018 www.prnewswire.com - April 25 at 4:46 PM
	$780,000.00 in Sales Expected for AcelRx Pharmaceuticals (ACRX) This Quarter www.americanbankingnews.com - April 20 at 4:28 AM
	-$0.24 Earnings Per Share Expected for AcelRx Pharmaceuticals (ACRX) This Quarter www.americanbankingnews.com - April 18 at 8:32 AM
	Pharmacokinetics of AcelRx Pharma's sublingual sufentanil supports effectiveness in monitored setting; shares up 4% premarket seekingalpha.com - April 18 at 8:16 AM
	AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting finance.yahoo.com - April 18 at 8:16 AM
	Blog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIA finance.yahoo.com - April 18 at 8:16 AM
	AcelRx Pharmaceuticals (ACRX) Upgraded to "Hold" at ValuEngine www.americanbankingnews.com - April 16 at 7:34 PM
	AcelRx completes the human factors study for DSUVIA; plans to resubmit NDA in Q2 seekingalpha.com - April 16 at 8:15 AM
	AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018 finance.yahoo.com - April 16 at 8:15 AM
	AcelRx Pharmaceuticals (ACRX) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 14 at 2:30 PM
	AcelRx Pharmaceuticals (ACRX) Stock Rating Reaffirmed by Cowen www.americanbankingnews.com - April 14 at 11:48 AM
	AcelRx Pharmaceuticals (ACRX) Lifted to "Buy" at Stifel Nicolaus www.americanbankingnews.com - April 12 at 12:29 AM
	AcelRx Pharmaceuticals (ACRX) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - April 11 at 5:43 PM
	AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe finance.yahoo.com - April 11 at 5:32 PM

AcelRx Pharmaceuticals (NASDAQ:ACRX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

AcelRx Pharmaceuticals (NASDAQ:ACRX) Income Statement, Balance Sheet and Cash Flow Statement

AcelRx Pharmaceuticals (NASDAQ ACRX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff